Literature DB >> 17893884

The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development.

G Liu1, T Terzian, S Xiong, C S Van Pelt, A Audiffred, N F Box, G Lozano.   

Abstract

Mdm2, an E3 ubiquitin ligase, negatively regulates the tumour suppressor p53. Loss of Mdm2 in mice results in p53-dependent apoptosis and embryonic lethality. This phenotype was rescued by the p53(515C) allele, which encodes an apoptosis-deficient p53R172P protein. However, these mice died within 2 weeks of birth, due to a severe impairment of progenitor cell expansion during postnatal haematopoiesis and cerebellar development, leading to p53-dependent cell cycle arrest. Loss of Mdm2 led to phosphorylation of the p53R172P protein, p53R172P stability and activation of the cell cycle inhibitor p21 in proliferating cells, but not in differentiated cells, in multiple tissue compartments. Proliferating cells of epithelial origin were not affected. The haematopoietic and neural defects were alleviated in mice lacking Mdm2 and containing one p53(515C) and one p53-null allele, but spermatogenesis was arrested. These findings establish a crucial role for the p53-Mdm2 network in regulating proliferation and progenitor expansion in many cell lineages and have important implications for the use of drugs that aim to disrupt the p53-Mdm2 interaction. (c) 2007 Pathological Scoiety of Great Britain and Ireland

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17893884     DOI: 10.1002/path.2238

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  36 in total

Review 1.  Mouse models of p53 functions.

Authors:  Guillermina Lozano
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

2.  p53 and MDM2 are involved in the regulation of osteocalcin gene expression.

Authors:  Hankui Chen; Kevin Kolman; Natalie Lanciloti; Michael Nerney; Emily Hays; Chet Robson; Nalini Chandar
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

3.  The ups and downs of p53 regulation in hematopoietic stem cells.

Authors:  Hussein A Abbas; Vinod Pant; Guillermina Lozano
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

4.  Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity.

Authors:  Hussein A Abbas; Daniela R Maccio; Suleyman Coskun; James G Jackson; Amy L Hazen; Tiffany M Sills; M James You; Karen K Hirschi; Guillermina Lozano
Journal:  Cell Stem Cell       Date:  2010-11-05       Impact factor: 24.633

5.  Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models.

Authors:  Tamara Terzian; Melissa Dumble; Farinaz Arbab; Christina Thaller; Lawrence A Donehower; Guillermina Lozano; Monica J Justice; Dennis R Roop; Neil F Box
Journal:  J Pathol       Date:  2011-06-14       Impact factor: 7.996

6.  DNMT1 represses p53 to maintain progenitor cell survival during pancreatic organogenesis.

Authors:  Senta Georgia; Murtaza Kanji; Anil Bhushan
Journal:  Genes Dev       Date:  2013-02-15       Impact factor: 11.361

7.  It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53.

Authors:  Ian M Love; Steven R Grossman
Journal:  Genes Cancer       Date:  2012-03

Review 8.  The Tail That Wags the Dog: How the Disordered C-Terminal Domain Controls the Transcriptional Activities of the p53 Tumor-Suppressor Protein.

Authors:  Oleg Laptenko; David R Tong; James Manfredi; Carol Prives
Journal:  Trends Biochem Sci       Date:  2016-09-23       Impact factor: 13.807

9.  Guilty as CHARGED: p53's expanding role in disease.

Authors:  Jeanine L Van Nostrand; Laura D Attardi
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  Apoptosis gene profiling reveals spatio-temporal regulated expression of the p53/Mdm2 pathway during lens development.

Authors:  Jenny C Geatrell; Peng Mui Iryn Gan; Fiona C Mansergh; Lilian Kisiswa; Miguel Jarrin; Llinos A Williams; Martin J Evans; Mike E Boulton; Michael A Wride
Journal:  Exp Eye Res       Date:  2009-02-11       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.